363 related articles for article (PubMed ID: 19708067)
1. An evaluation of the mode of action framework for mutagenic carcinogens case study II: chromium (VI).
McCarroll N; Keshava N; Chen J; Akerman G; Kligerman A; Rinde E
Environ Mol Mutagen; 2010 Mar; 51(2):89-111. PubMed ID: 19708067
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
[TBL] [Abstract][Full Text] [Related]
3. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: an in silico comparison with mutagenic and nonmutagenic carcinogens across tissues.
Thompson CM; Gregory Hixon J; Proctor DM; Haws LC; Suh M; Urban JD; Harris MA
Regul Toxicol Pharmacol; 2012 Oct; 64(1):68-76. PubMed ID: 22705708
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures.
Proctor DM; Suh M; Campleman SL; Thompson CM
Toxicology; 2014 Nov; 325():160-79. PubMed ID: 25174529
[TBL] [Abstract][Full Text] [Related]
5. Is hexavalent chromium carcinogenic via ingestion? A weight-of-evidence review.
Proctor DM; Otani JM; Finley BL; Paustenbach DJ; Bland JA; Speizer N; Sargent EV
J Toxicol Environ Health A; 2002 May; 65(10):701-46. PubMed ID: 12028825
[TBL] [Abstract][Full Text] [Related]
6. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
8. Tracing the tracks of genotoxicity by trivalent and hexavalent chromium in Drosophila melanogaster.
Mishra M; Sharma A; Negi MP; Dwivedi UN; Chowdhuri DK
Mutat Res; 2011 May; 722(1):44-51. PubMed ID: 21382505
[TBL] [Abstract][Full Text] [Related]
9. Chromium(VI) enhances (+/-)-anti-7beta,8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-induced cytotoxicity and mutagenicity in mammalian cells through its inhibitory effect on nucleotide excision repair.
Hu W; Feng Z; Tang MS
Biochemistry; 2004 Nov; 43(44):14282-9. PubMed ID: 15518579
[TBL] [Abstract][Full Text] [Related]
10. Use of genetic toxicology information for risk assessment.
Dearfield KL; Moore MM
Environ Mol Mutagen; 2005 Dec; 46(4):236-45. PubMed ID: 16258925
[TBL] [Abstract][Full Text] [Related]
11. Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents.
Thompson CM; Suh M; Proctor DM; Haws LC; Harris MA
Mutat Res Genet Toxicol Environ Mutagen; 2017 Nov; 823():45-57. PubMed ID: 28985946
[TBL] [Abstract][Full Text] [Related]
12. Chromium in drinking water: sources, metabolism, and cancer risks.
Zhitkovich A
Chem Res Toxicol; 2011 Oct; 24(10):1617-29. PubMed ID: 21766833
[TBL] [Abstract][Full Text] [Related]
13. Intracellular and extracellular factors influencing Cr(VI) and Cr(III) genotoxicity.
Sobol Z; Schiestl RH
Environ Mol Mutagen; 2012 Mar; 53(2):94-100. PubMed ID: 22020802
[TBL] [Abstract][Full Text] [Related]
14. Characterization of nonmutagenic Cr(III)-DNA interactions.
Blankert SA; Coryell VH; Picard BT; Wolf KK; Lomas RE; Stearns DM
Chem Res Toxicol; 2003 Jul; 16(7):847-54. PubMed ID: 12870887
[TBL] [Abstract][Full Text] [Related]
15. Lack of genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving chromium(VI) with the drinking water.
De Flora S; D'Agostini F; Balansky R; Micale R; Baluce B; Izzotti A
Mutat Res; 2008; 659(1-2):60-7. PubMed ID: 18155955
[TBL] [Abstract][Full Text] [Related]
16. Framework analysis for the carcinogenic mode of action of nitrobenzene.
Hsu CH; Stedeford T; Okochi-Takada E; Ushijima T; Noguchi H; Muro-Cacho C; Holder JW; Banasik M
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(2):155-84. PubMed ID: 17558784
[TBL] [Abstract][Full Text] [Related]
17. Mutagenicity of bromate: implications for cancer risk assessment.
Moore MM; Chen T
Toxicology; 2006 Apr; 221(2-3):190-6. PubMed ID: 16460860
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium.
Thompson CM; Bichteler A; Rager JE; Suh M; Proctor DM; Haws LC; Harris MA
Mutat Res Genet Toxicol Environ Mutagen; 2016 Apr; 800-801():28-34. PubMed ID: 27085472
[TBL] [Abstract][Full Text] [Related]
19. Genotoxicity and mutagenicity of chromium(VI)/ascorbate-generated DNA adducts in human and bacterial cells.
Quievryn G; Peterson E; Messer J; Zhitkovich A
Biochemistry; 2003 Feb; 42(4):1062-70. PubMed ID: 12549927
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the mutagenic potential of Cr(VI) in the oral mucosa of Big Blue® transgenic F344 rats.
Thompson CM; Young RR; Suh M; Dinesdurage HR; Elbekai RH; Harris MA; Rohr AC; Proctor DM
Environ Mol Mutagen; 2015 Aug; 56(7):621-8. PubMed ID: 26010270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
